ARCA biopharma, Inc (ABIO)

Etorro trading 970x250

About ARCA biopharma, Inc

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado. Address: 10170 Church Ranch Way, Westminster, CO, United States, 80021

ARCA biopharma, Inc News and around…

Latest news about ARCA biopharma, Inc (ABIO) common stock and company :

ARCA biopharma Announces Second Quarter 2022 Financial Results
02 Aug, 2022 Yahoo! Finance

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s Pr

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
18 Jul, 2022 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors
21 Jun, 2022 Yahoo! Finance

WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. “We are pleased to welcome Jacob Ma-Weaver, the managing member of ARCA’s largest shareholder, to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input as we explore and evaluate strategic options for maximizing stockholder value.” Mr. Ma-Weaver is the Managing Member of Cab

12 Health Care Stocks Moving In Friday's After-Market Session
17 Jun, 2022 FinancialContent

Gainers Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value ...

CPC Clinical Research Announces Dr. Connie Hess Receives Paul Dudley White Award For rNAPc2 in COVID 19 Presentation at the American Heart Association Vascular Discovery Scientific Sessions
17 May, 2022 FinancialContent

AURORA, CO / ACCESSWIRE / May 17, 2022 / CPC Clinical Research, an academic research organization recognized for its expertise in comprehensive clinical trial design and management, announced that Dr. Connie Hess presented results from the ASPEN-COVID-19 clinical trial at the American Heart Association Vascular Discovery Scientific Sessions held May 12-14, 2022 in Seattle, Washington. Dr. Hess received the American Heart Association 2022 Paul Dudley White International Scholar Award, which is presented to the primary author of the highest ranked abstract submitted from each country to the conference. The clinical trial was conducted on behalf of ARCA biopharma, Inc. (NASDAQ:ABIO).

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
05 May, 2022 Yahoo! Finance

WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 2022, the Board of Directors established a Special Committee to explore and evaluate strategic options for maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or

ARCA biopharma Announces First Quarter 2022 Financial Results
02 May, 2022 Yahoo! Finance

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s Pres

12 Health Care Stocks Moving In Monday's After-Market Session
18 Apr, 2022 FinancialContent

Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands ...

ARCA biopharma Establishes Special Committee of the Board of Directors
18 Apr, 2022 Yahoo! Finance

WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that its Board of Directors has established a Special Committee to evaluate strategic options for maximizing stockholder value. The Company believes there are multiple potential opportunities to enhance value for ARCA stockholders. The Special Committ

Albioma : Governance changes
05 Apr, 2022 Yahoo! Finance

Press release Paris La Défense, 5 April 2022 Governance changes Marie-Claire Daveu has informed Albioma today of her intention to resign from the Board of Directors with effect from 31 July 2022, with her appointment as Director to be submitted to Engie's General Meeting of Shareholders shortly. The composition of the Board of Directors of Albioma will be reviewed accordingly in the coming months. Frédéric Moyne, Chairman and CEO of Albioma, said: “I would like to join all the directors in thank

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
04 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you're looking for the biggest pre-market stock movers for Monday, we've got you covered with a list of gainers and losers for today. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Get in Now on Tiny $3 ‘Forever Battery’ Stock It doesn’t matter if you have $500 in savings or $5 million. Do this now. Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

26 Stocks Moving in Monday's Pre-Market Session
04 Apr, 2022 FinancialContent

Gainers SPI Energy Co., Ltd. (NASDAQ: SPI) rose 36.3% to $3.87 in pre-market trading after reporting record revenue of $162 ...

38 Stocks Moving In Friday's Mid-Day Session
01 Apr, 2022 FinancialContent

Gainers Manning & Napier, Inc. (NYSE: MN) jumped 40.7% to $12.82 after the company reported it will be acquired by Callodine ...

Mid-Morning Market Update: Markets Higher; US Economy Adds 431,000 Jobs In March
01 Apr, 2022 FinancialContent

U.S. stocks opened higher this morning following the release of non-farm payroll data for March. The Dow traded up 0.17% to 34,735.64 ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
01 Apr, 2022 FinancialContent

Gainers Yumanity Therapeutics (NASDAQ:YMTX) shares rose 13.3% to $1.7 during Friday's pre-market session. The market ...

The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study
01 Apr, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Reata Completes Regulatory ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
01 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! It's the last trading day of the week and that means it's time to get into the pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Get in Now on Tiny $3 ‘Forever Battery’ Stock It doesn’t matter if you have $500 in savings or $5 million. Do this now. Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study
01 Apr, 2022 FinancialContent

ARCA biopharma Inc(NASDAQ: ABIO) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor ...

21 Stocks Moving in Friday's Pre-Market Session
01 Apr, 2022 FinancialContent

Gainers Blackboxstocks Inc. (NASDAQ: BLBX) rose 37.6% to $3.69 in pre-market trading after the company reported ...

ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial
31 Mar, 2022 Yahoo! Finance

Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. For the entire cohort of COVID-19 hospitalized patients, the pooled lower and higher rNAPc2 dose groups demonstrated a reduction compared to baseline in D-dimer levels of 16.8% versus 11.2% for standard of care heparin which was not statistically significant and consequently did not achieve the study primary endpointThe treatment effects of rNAPc2 and heparin were different in Mild versus Severe categories of an adapted WHO

A few names on my watchlist for the coming week
27 Mar, 2022 FinancialContent
Developing Biopharma Plays to Look at Now (STAB, MEIP, ABIO, AMPE, ZIVO, MREO)
15 Mar, 2022 FinancialContent
ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update
14 Mar, 2022 Yahoo! Finance

Topline data from Phase 2b ASPEN-COVID-19 clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the last week of March 2022WESTMINSTER, Colo., March 14, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2021 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and

Battalion Oil Corporation Announces Fourth Quarter and Full Year 2021 Financial and Operating Results
07 Mar, 2022 Yahoo! Finance

HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Battalion Oil Corporation (NYSE American: BATL, “Battalion” or the “Company”) today announced financial and operating results for the fourth quarter and full year 2021. Key Highlights Reported average daily production of 17,283 Boepd and 16,241 Boepd in fourth quarter and full year 2021, respectivelyProved reserves of 95.9 MMBoe, a 51% increase over year-end 2020 reservesCompleted strategic refinancing in November 2021; enhanced liquidity profile allow

We're Keeping An Eye On ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate
08 Feb, 2022 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2
04 Jan, 2022 Yahoo! Finance

Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF)In a Phase 2B clinical trial, the prevalence of clinically important bradycardia was statistically significantly lower for GencaroTM compared to metoprolol WESTMINSTER, Colo., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision med

ARCA Biopharma Expects Data Readout From Mid-Stage COVID-19 Trial In Q1 2022
02 Dec, 2021 FinancialContent

ARCA biopharma Inc(NASDAQ: ABIO)has completed enrollmentof 160 patients in ASPEN-COVID-19 Phase 2b trial evaluating ...

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19
02 Dec, 2021 Yahoo! Finance

Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. Topline readout of clinical trial results anticipated in first quarter of 2022 WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing targeted therapies for cardiovascular diseases, today announced that enrollment has been completed in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potenti

5 Penny Stocks Insiders Are Buying
24 Nov, 2021 FinancialContent

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors ...

Extreme oversold stocks for Thanksgiving week
20 Nov, 2021 FinancialContent

ARCA biopharma, Inc (ABIO) is a NASDAQ Common Stock listed in , ,

970x250